Alto Neuroscience Inc (ANRO)

NYSEHealth CareBiotechnologySnapshot 2026-10-23

$21.97-1.04%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Alto Neuroscience Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.695
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-2.785
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-3.006

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash balance to support operations through 2029	Alto Neuroscience is focused on maintaining cash to fund operations through 2029.	Intact	Cash balance falls below levels needed to fund operations through 2029	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance clinical development programs	Operating losses are managed while advancing clinical programs.	Intact	Significant clinical trial failures or delays	No clinical failures reported; $100M raised to fund ALTO-207 expansion Company raised $100M and expanded ALTO-207 plans. No news of clinical setbacks or delays. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage operating losses and cash burn	Operating losses are managed while advancing clinical programs.	Intact	Operating losses increase materially beyond -$27.1M	Operating income: $-29.129M FY2026-Q2; GAAP. Published target: Operating losses do not worsen beyond -$27.1M next quarter. Target period is not explicitly aligned with this observation. Source published Aug 12, 2026-29,129,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 63b56db1-9eca-4ee4-b46e-feca9a74ab4e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-3.01

$-3.21 → $-3.01 · observed estimates

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-3.21	Unavailable	8 / 0
2026-07-25	$-3.21	Unavailable	8 / 0
2026-07-26	$-3.21	Unavailable	8 / 0
2026-07-27	$-3.21	Unavailable	8 / 0
2026-07-28	$-3.21	Unavailable	8 / 0
2026-07-29	$-3.43	$0	6 / 10
2026-07-30	$-3.43	$0	6 / 10
2026-07-31	$-3.43	$0	6 / 10
2026-08-01	$-3.43	$0	6 / 10
2026-08-02	$-3.43	$0	6 / 10
2026-08-03	$-3.43	$0	6 / 10
2026-08-04	$-3.43	$0	6 / 10
2026-08-05	$-3.43	$0	6 / 10
2026-08-06	$-3.43	$0	6 / 10
2026-08-07	$-3.29	Unavailable	7 / 0
2026-08-08	$-3.43	$0	6 / 10
2026-08-09	$-3.43	$0	6 / 10
2026-08-10	$-3.43	$0	6 / 10
2026-08-11	$-3.29	Unavailable	7 / 0
2026-08-12	$-3.43	$0	6 / 10
2026-08-13	$-3.43	$0	6 / 10
2026-08-14	$-3.29	Unavailable	7 / 0
2026-08-15	$-3.29	Unavailable	8 / 0
2026-08-16	$-3.29	Unavailable	8 / 0
2026-08-17	$-3.29	Unavailable	8 / 0
2026-08-18	$-3.29	Unavailable	8 / 0
2026-08-19	$-3.29	Unavailable	8 / 0
2026-08-20	$-3.07	Unavailable	8 / 0
2026-08-21	$-3.07	Unavailable	8 / 0
2026-08-22	$-3.07	Unavailable	8 / 0
2026-08-23	$-3.07	Unavailable	8 / 0
2026-08-24	$-3.07	Unavailable	8 / 0
2026-08-25	$-3.07	Unavailable	8 / 0
2026-08-26	$-3.07	Unavailable	8 / 0
2026-08-27	$-3.07	Unavailable	8 / 0
2026-08-28	$-3.07	Unavailable	8 / 0
2026-08-29	$-3.07	Unavailable	8 / 0
2026-08-30	$-3.07	Unavailable	8 / 0
2026-08-31	$-3.07	Unavailable	8 / 0
2026-09-01	$-3.07	Unavailable	8 / 0
2026-09-02	$-3.07	Unavailable	8 / 0
2026-09-03	$-3.07	Unavailable	8 / 0
2026-09-04	$-3.07	Unavailable	8 / 0
2026-09-05	$-3.07	Unavailable	8 / 0
2026-09-06	$-3.07	Unavailable	8 / 0
2026-09-07	$-3.07	Unavailable	8 / 0
2026-09-08	$-3.07	Unavailable	8 / 0
2026-09-09	$-3.07	Unavailable	8 / 0
2026-09-10	$-3.07	Unavailable	8 / 0
2026-09-11	$-3.07	Unavailable	8 / 0
2026-09-12	$-3.07	Unavailable	8 / 0
2026-09-13	$-3.07	Unavailable	8 / 0
2026-09-14	$-3.07	Unavailable	8 / 0
2026-09-15	$-3.07	Unavailable	8 / 0
2026-09-16	$-3.07	Unavailable	8 / 0
2026-09-17	$-3.07	Unavailable	8 / 0
2026-09-18	$-3.07	Unavailable	8 / 0
2026-09-19	$-3.07	Unavailable	8 / 0
2026-09-20	$-3.07	Unavailable	8 / 0
2026-09-21	$-3.07	Unavailable	8 / 0
2026-09-22	$-3.07	Unavailable	8 / 0
2026-09-23	$-3.07	Unavailable	8 / 0
2026-09-24	$-3.07	Unavailable	8 / 0
2026-09-25	$-3.07	Unavailable	8 / 0
2026-09-26	$-3.07	Unavailable	8 / 0
2026-09-27	$-3.07	Unavailable	8 / 0
2026-09-28	$-3.07	Unavailable	8 / 0
2026-09-29	$-3.07	Unavailable	8 / 0
2026-09-30	$-3.07	Unavailable	8 / 0
2026-10-01	$-3.07	Unavailable	8 / 0
2026-10-02	$-3.07	Unavailable	8 / 0
2026-10-03	$-3.07	Unavailable	8 / 0
2026-10-04	$-3.07	Unavailable	8 / 0
2026-10-05	$-3.07	Unavailable	8 / 0
2026-10-06	$-3.07	Unavailable	8 / 0
2026-10-07	$-3.07	Unavailable	8 / 0
2026-10-08	$-3.07	Unavailable	8 / 0
2026-10-09	$-3.07	Unavailable	8 / 0
2026-10-10	$-3.07	Unavailable	8 / 0
2026-10-11	$-3.07	Unavailable	8 / 0
2026-10-12	$-3.07	Unavailable	8 / 0
2026-10-13	$-3.07	Unavailable	8 / 0
2026-10-14	$-3.07	Unavailable	8 / 0
2026-10-15	$-3.07	Unavailable	8 / 0
2026-10-16	$-3.07	Unavailable	8 / 0
2026-10-17	$-3.07	Unavailable	8 / 0
2026-10-18	$-3.07	Unavailable	8 / 0
2026-10-19	$-3.07	Unavailable	8 / 0
2026-10-20	$-3.07	Unavailable	8 / 0
2026-10-21	$-3.01	Unavailable	8 / 0
2026-10-22	$-3.01	Unavailable	8 / 0
2026-10-23	$-3.01	Unavailable	8 / 0
2026-10-24	$-3.01	Unavailable	8 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	11	1
2026-06-01	11	1
2026-07-01	11	1
2026-08-01	10	1
2026-09-01	10	1
2026-10-01	10	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

H.C. WainwrightOct 19 · prior Aug 17

$55.00 → $60.00+9.1%

$0$33.00$66.00

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash balance to support operations through 2029Direct metric needs a verified mapping
Manage operating losses and cash burnOperating income: $-29.129M

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.9%Typical daily move · historical

Downside history

-40.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Alto Neuroscience Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-development company, not an established earnings compounder, because it is loss-making and its results are weak. The thesis is in a watch state: management is progressing its main trial plans and reports cash runway through 2029–2030, but confidence in the overall evidence is low.

What's priced into Alto Neuroscience Inc

The snapshot gives no usable valuation comparison or clear account of market expectations, so whether ANRO is cheap, fair, or expensive versus peers cannot be assessed. It reports low fragility in priced-in signals, while the recent thesis response has been muted; neither establishes how much clinical progress the market already assumes.

What the fundamentals likely do

Near term, ANRO remains loss-making, with recent financial performance rated weak and an elevated risk of a miss at the next report. An August earnings beat is a positive event, but it does not change the broader weak-performance assessment. Over the multi-year view, ALTO-207 Phase 2b enrollment is reported on track, with topline data expected in the second half of 2027 and Phase 3 trials planned for 2027; reported cash is expected to fund operations through 2029–2030.

What Alto Neuroscience Inc hinges on

The thesis depends on ALTO-207 trial progress, data quality, and whether the planned studies produce useful results; patient-screening measures are new, and their delivery is not yet assessable. A guidance cut or further weakening in the jobs trend could add pressure, while stronger results and guidance from healthcare bellwethers could support sector sentiment.